Perifosine gets FDA fast-track status as colorectal cancer drug

04/5/2010 | Bloomberg Businessweek

The FDA gave fast-track review designation to perifosine, Aeterna Zentaris and Keryx Biopharmaceuticals' experimental treatment for refractory advanced colorectal cancer. Perifosine already has orphan-drug status as well as fast-track status for its use against multiple myeloma.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN